ASD vs PPH
Defiance Autism Impact ETF against VanEck Pharmaceutical ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
13%
6 shared positions
Fee gap
43 bp
PPH is cheaper
1-year return gap
—
Larger fund
PPH
$1.0B
Side by side
| ASD | PPH | |
|---|---|---|
| Fund | Defiance Autism Impact ETF | VanEck Pharmaceutical ETF |
| Issuer | Defiance | VanEck |
| Category | ESG & Values | Health Care |
| Expense ratio | 0.79% | 0.36% |
| Assets | $1.4M | $1.0B |
| Average daily dollar volume | $7K | $32M |
| Listed | Jun 1, 2026 | Dec 20, 2011 |
| FrenzyCap score | 16 | 62 |
| 1-month return | −1.2% | +0.8% |
| 3-month return | −1.4% | +1.6% |
| Year to date | — | +7.1% |
| 1-year return | — | +18.3% |
| 30-day volatility | 12.1% | 16.1% |
| Worst drawdown, 1 year | −7.7% | −11.5% |
| Trailing 12-month yield | 0.03% | 1.94% |
| Holdings | 39 | 27 |
| Top 10 weight | 30.8% | 71.5% |
| Look-through P/E | — | 39.0 |
| Holdings vs fair value | +17.6% | +5.2% |
| Holdings above 200-day average | 55% | 67% |
| Net flow, latest 3 reported months | +$1.3M thru Jun 2026 | −$449M thru Jun 2026 |
| 30-day implied volatility | — | 20.7% |
| Holdings as of | as of Jun 30, 2026SEC filing | as of Oct 8, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
17% of ASD · 38% of PPH
Sector mix of the stock holdings
| Sector | ASD | PPH | Gap |
|---|---|---|---|
| Health Care | 46.8% | 96.1% | −49.3% |
| Consumer Discretionary | 6.8% | 0.0% | +6.8% |
| Consumer Staples | 0.0% | 3.8% | −3.8% |
| Technology | 2.7% | 0.0% | +2.7% |
| Other | 2.7% | 0.0% | +2.7% |
More: full overlap table · ASD holdings · PPH holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.